---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-117144"
form_type: "8-K"
ticker: "ALT"
cik: "0001326190"
company_name: "Altimmune, Inc."
filed_at: "2025-12-01T23:59:59+00:00"
generated_at: "2026-05-16T15:51:39.410351+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Altimmune CEO Vipin Garg to step down Jan 1, 2026; Chairman Jerome Durso named successor

## Summary
- Vipin Garg transitions from President/CEO to advisor through June 30, 2026; remains on board until Jan 31, 2026.
- Jerome Durso, current Chairman and former Intercept CEO, becomes President and CEO effective Jan 1, 2026.
- Durso receives annual base salary of $725,000, target bonus 60% of base, and equity grants of 633,700 RSUs and 1,824,400 stock options.
- Garg will receive severance: 12 months base salary, COBRA subsidy, continued equity vesting through separation date.
- Altimmune expects End-of-Phase 2 FDA meeting this quarter and 48-week IMPACT data before year-end for pemvidutide in MASH.

## SEC filing metadata
- accession: 0001104659-25-117144
- form_type: 8-K
- ticker: ALT
- cik: 0001326190
- company_name: Altimmune, Inc.
- filed_at: 2025-12-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326190/000110465925117144/0001104659-25-117144-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326190/000110465925117144/tm2532420d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-117144
- JSON: https://secwatch.observer/filing/0001104659-25-117144.json
- Plain text: https://secwatch.observer/filing/0001104659-25-117144.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.